Nova Patents
MA29014B1

Antibody formulations

Abstract

The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

70 members in 36 offices

This recordMember, by publication datePriority claim26 more offices are in the list below

Priority claims4

Priority claims
DocumentOfficeKindDate
62041304United States of AmericaP
62041304United States of AmericaP
60620413–––
US20040620413P–––

Members70

Family members, oldest first
DocumentOfficeKind
SV2006002275AEl SalvadorA
AU2005295394A1AustraliaA1
CA2579861A1CanadaA1
US2006088523A1United States of AmericaA1
WO2006044908A2World Intellectual Property Organization (WIPO)A2
GT200500298AGuatemalaA
TW200618811ATaiwan Province of ChinaA
WO2006044908A3World Intellectual Property Organization (WIPO)A3
PE20061043A1PeruA1
PA8650001A1PanamaA1
ECSP077308AEcuadorA
KR20070068385ARepublic of KoreaA
EP1802344A2European Patent Office (EPO)A2
IL181738D0IsraelD0
NO20072513LNorwayL
MA29014B1This recordMoroccoB1
CN101084015AChinaA
HK1104483A1Hong Kong, ChinaA1
HK1108391A1Hong Kong, ChinaA1
TNSN07088A1TunisiaA1
JP2008520551AJapanA
ZA200702521BSouth AfricaB
BRPI0516299ABrazilA
RU2007118648ARussian FederationA
CR9129ACosta RicaA
PE20091327A1PeruA1
NZ553625ANew ZealandA
US2010015157A1United States of AmericaA1
UA89798C2UkraineC2
IL211393D0IsraelD0
AU2005295394B2AustraliaB2
CN101084015BChinaB
RU2426554C2Russian FederationC2
EP2371388A2European Patent Office (EPO)A2
CN102319430AChinaA
EP2371388A3European Patent Office (EPO)A3
MY146100AMalaysiaA
EP1802344B1European Patent Office (EPO)B1
RU2011104955ARussian FederationA
JP5025482B2JapanB2
JP2012176970AJapanA
DK1802344T3DenmarkT3
ES2389911T3SpainT3
PT1802344EPortugalE
HRP20120893T1CroatiaT1
SI1802344T1SloveniaT1
CA2579861CCanadaC
PL1802344T3PolandT3
US8372396B2United States of AmericaB2
KR101243590B1Republic of KoreaB1
US2013071384A1United States of AmericaA1
RS52512BSerbiaB
TWI394582BTaiwan Province of ChinaB
SG196859A1SingaporeA1
JP2014159469AJapanA
US9017671B2United States of AmericaB2
IL181738AIsraelA
IL237756D0IsraelD0
US2015196642A1United States of AmericaA1
JP2016065091AJapanA
IL211393AIsraelA
CY1113407T1CyprusT1
JO3000B1JordanB1
US2018221488A1United States of AmericaA1
NO343683B1NorwayB1
EP3498294A1European Patent Office (EPO)A1
US2020179515A1United States of AmericaA1
BRPI0516299B1BrazilB1
BRPI0516299B8BrazilB8
US2023263895A1United States of AmericaA1